<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>40</volume><submitter>Taylor JA</submitter><funding>US Department of Defense</funding><pubmed_abstract>Recently, the diagnosis of autism spectrum disorder (ASD) has increased from 1 in 150 to every 1 in 36 children in the United States, warranting a need for novel prevention and therapeutic strategies. Broad-spectrum cannabidiol oil, free from delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, may be one such therapeutic. It has a high safety profile and is frequently used as a complementary and integrative intervention by persons experiencing symptoms of anxiety, stress, and inflammation. Using a neurodevelopmental rat model of ASD (based on neuroinflammation induced by stress and terbutaline exposure during pre- and postnatal development), we sought to prevent the development of ASD-like behaviors in male offspring by administering broad-spectrum cannabidiol oil to dams</pubmed_abstract><journal>Brain, behavior, &amp; immunity - health</journal><pagination>100828</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11337682</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prenatal broad-spectrum cannabidiol administration prevents an autism-like phenotype in male offspring from a maternal stress/terbutaline rat model.</pubmed_title><pmcid>PMC11337682</pmcid><pubmed_authors>Taylor JA</pubmed_authors><pubmed_authors>Smith ZZ</pubmed_authors><pubmed_authors>Lowry CA</pubmed_authors><pubmed_authors>Reuter JD</pubmed_authors><pubmed_authors>Holbrook EM</pubmed_authors><pubmed_authors>Barth DS</pubmed_authors><pubmed_authors>Anderson ME</pubmed_authors><pubmed_authors>Elkinbard IS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prenatal broad-spectrum cannabidiol administration prevents an autism-like phenotype in male offspring from a maternal stress/terbutaline rat model.</name><description>Recently, the diagnosis of autism spectrum disorder (ASD) has increased from 1 in 150 to every 1 in 36 children in the United States, warranting a need for novel prevention and therapeutic strategies. Broad-spectrum cannabidiol oil, free from delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, may be one such therapeutic. It has a high safety profile and is frequently used as a complementary and integrative intervention by persons experiencing symptoms of anxiety, stress, and inflammation. Using a neurodevelopmental rat model of ASD (based on neuroinflammation induced by stress and terbutaline exposure during pre- and postnatal development), we sought to prevent the development of ASD-like behaviors in male offspring by administering broad-spectrum cannabidiol oil to dams</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2025-04-04T03:09:57.24Z</modification><creation>2025-04-04T03:09:57.24Z</creation></dates><accession>S-EPMC11337682</accession><cross_references><pubmed>39170798</pubmed><doi>10.1016/j.bbih.2024.100828</doi></cross_references></HashMap>